The Market

The global market for the treatment of erectile dysfunction and premature ejaculation was valued at USD 8 billion in 2023. This sales figure is also expected to increase by 50% by 2029.

The significant market growth is driven by an aging population, an increased prevalence of underlying conditions such as diabetes, and greater accessibility to treatments via digital healthcare providers.

Today, the market is dominated by PDE5 inhibitors, such as Viagra. These medications were revolutionary when they were introduced in the late 1990s. However, they have their limitations, and there has been little new development since then. Therefore, there is a clear need for new medications with longer-lasting effects, fewer side effects, and that can help patient groups who currently do not benefit from PDE5 inhibitors.

When it comes to the treatment of premature ejaculation, the availability of effective treatments on the market is still very limited.

Dicot's drug candidate targets the treatment of both dysfunctions, either individually or in combination. According to available information, such dual-action treatment is unique. A Phase 1 study has already been conducted for the erectile dysfunction indication.